Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Background Endoscopic sleeve gastroplasty (ESG) is an endolumenal, organ-sparing therapy for obesity, with wide global adoption. We aimed to explore the efficacy and safety of ESG with lifestyle modifications compared with lifestyle modifications alone.Methods We conducted a randomised clinical trial at nine US centres, enrolling individuals aged 21-65 years with class 1 or class 2 obesity and who agreed to comply with lifelong dietary restrictions. Participants were randomly assigned (1:1·5; with stratified permuted blocks) to ESG with lifestyle modifications (ESG group) or lifestyle modifications alone (control group), with potential retightening or crossover to ESG, respectively, at 52 weeks. Lifestyle modifications included a low-calorie diet and physical activity. Participants in the primary ESG group were followed up for 104 weeks. The primary endpoint at 52 weeks was the percentage of excess weight loss (EWL), with excess weight being that over the ideal weight for a BMI of 25 kg/m 2. Secondary endpoints included change in metabolic comorbidities between the groups. We used multiple imputed intention-to-treat analyses with mixed-effects models. Our analyses were done on a per-protocol basis and a modified intention-to-treat basis. The safety population was defined as all participants who underwent ESG (both primary and crossover ESG) up to 52 weeks.Findings Between Dec 20, 2017, and June 14, 2019, 209 participants were randomly assigned to ESG (n=85) or to control (n=124). At 52 weeks, the primary endpoint of mean percentage of EWL was 49·2% (SD 32·0) for the ESG group and 3·2% (18·6) for the control group (p<0·0001). Mean percentage of total bodyweight loss was 13·6% (8·0) for the ESG group and 0·8% (5·0) for the control group (p<0·0001), and 59 (77%) of 77 participants in the ESG group reached 25% or more of EWL at 52 weeks compared with 13 (12%) of 110 in the control group (p<0·0001). At 52 weeks, 41 (80%) of 51 participants in the ESG group had an improvement in one or more metabolic comorbidities, whereas six (12%) worsened, compared with the control group in which 28 (45%) of 62 participants had similar improvement, whereas 31 (50%) worsened. At 104 weeks, 41 (68%) of 60 participants in the ESG group maintained 25% or more of EWL. ESG-related serious adverse events occurred in three (2%) of 131 participants, without mortality or need for intensive care or surgery.Interpretation ESG is a safe intervention that resulted in significant weight loss, maintained at 104 weeks, with important improvements in metabolic comorbidities. ESG should be considered as a synergistic weight loss intervention for patients with class 1 or class 2 obesity. This trial is registered with ClinicalTrials.gov, NCT03406975.Funding Apollo Endosurgery, Mayo Clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an RCT of 209 patients with obesity randomized to endoscopic sleeve gastroplasty plus lifestyle modifications (reduced-calorie diet and physical activity counseling) vs lifestyle modifications alone for 52 weeks,119 endoscopic sleeve gastroplasty achieved 13.6% weight loss compared with 0.8% with lifestyle modifications alone.119”
From Obesity Management in Adults: A Review (2023) · cites this paper as [119]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 30 · Cited by 338
Metadata
- Authors
- Abu Dayyeh, B. K., Bazerbachi, F., Vargas, E. J., Sharaiha, R. Z., Thompson, C. C., Thaemert, B. C., Teixeira, A. F., Chapman, C. G., Kumbhari, V., Ujiki, M. B., Ahrens, J., Day, C., Acosta, A. J., Badurdeen, D., Buttar, N. S., Clark, M. M., Eaton, L., Ghanem, O., Grothe, K., Jirapinyo, P., Kellogg, T., Klein, C. L., Mundi, M., Storm, A. C., Rivera, A. R., Wilson, T. D., Galvao Neto, M., Zundel, N., & Wilson, E. B.
- Affiliations
- St. Cloud Hospital (US)
- Mayo Clinic (US)
- Weill Cornell Medicine (US)
- Brigham and Women's Hospital (US)
- Avera McKennan Hospital & University Health Center (US)
- Orlando Health (US)
- University of Chicago (US)
- Endeavor Health (US)
- University at Buffalo, State University of New York (US)
- The University of Texas Health Science Center at Houston (US)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 400
- Issue
- 10350
- Pages
- 441-451
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4288458013
- Cited by
- 338
- References
- 30
- Citations by year
- 2026: 68 · 2025: 75 · 2024: 96 · 2023: 83 · 2022: 14
- FWCI
- 63.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Minimally Invasive Surgical Techniques
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- endoscopic sleeve gastroplasty, obesity, excess weight loss, lifestyle modification, hypocaloric diet, physical activity, metabolic comorbidities, treatment safety, weight loss efficacy
- MeSH terms
- Humans, Obesity, Prospective Studies, Gastroplasty, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)01280-6
- The paper
- Abu Dayyeh, B. K., Bazerbachi, F., Vargas, E. J., Sharaiha, R. Z., Thompson, C. C., Thaemert, B. C., Teixeira, A. F., Chapman, C. G., Kumbhari, V., Ujiki, M. B., Ahrens, J., Day, C., Acosta, A. J., Badurdeen, D., Buttar, N. S., Clark, M. M., Eaton, L., Ghanem, O., Grothe, K., . . . Wilson, E. B. (2022). Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)01280-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.